220
Views
3
CrossRef citations to date
0
Altmetric
Stakeholders View

Continued signs of resilience in the European drug market: Highlights from the EMCDDA’s 2016 European drug report

, , , , , & show all
Pages 492-495 | Received 29 Aug 2016, Accepted 27 Sep 2016, Published online: 15 Nov 2016
 

Acknowledgements

The authors would like to thank the many contributors to the EMCDDA EDR Trends and developments report, which this article summarises. The EDR is a collaborative effort and we acknowledge the invaluable contributions made by EMCDDA scientific staff and the Reitox network of National Focal Points.

Declaration of interest

There are no conflicts of interest to report.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.